Results of Radiation Therapy as Local Ablative Therapy for Oligometastatic Non-Small Cell Lung Cancer

Oligometastatic cancer is characterized by a limited number of metastatic deposits. Compared with lung cancer patients who have more widespread disease, oligometastatic lung cancer patients have more favorable survival outcomes. Therefore, it has been hypothesized that local ablative therapy (LAT) d...

Descripción completa

Guardado en:

Detalles Bibliográficos
Autores principales:	David L. Billing, Andreas Rimner
Formato:	article
Lenguaje:	EN
Publicado:	MDPI AG 2021
Materias:	oligometastatic non-small cell lung cancer radiotherapy stereotactic body radiotherapy local ablative therapy Neoplasms. Tumors. Oncology. Including cancer and carcinogens RC254-282
Acceso en línea:	https://doaj.org/article/117a3ad4f8d24511a647671c915dd762
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

id	oai:doaj.org-article:117a3ad4f8d24511a647671c915dd762
record_format	dspace
spelling	oai:doaj.org-article:117a3ad4f8d24511a647671c915dd7622021-11-25T17:03:48ZResults of Radiation Therapy as Local Ablative Therapy for Oligometastatic Non-Small Cell Lung Cancer10.3390/cancers132257732072-6694https://doaj.org/article/117a3ad4f8d24511a647671c915dd7622021-11-01T00:00:00Zhttps://www.mdpi.com/2072-6694/13/22/5773https://doaj.org/toc/2072-6694Oligometastatic cancer is characterized by a limited number of metastatic deposits. Compared with lung cancer patients who have more widespread disease, oligometastatic lung cancer patients have more favorable survival outcomes. Therefore, it has been hypothesized that local ablative therapy (LAT) directed at the metastatic deposits in addition to standard-of-care systemic therapy may further improve survival outcomes in oligometastatic lung cancer patients. One LAT modality that has been utilized in oligometastatic lung cancer is radiation therapy. In particular, ultra-hypofractionated radiotherapy, also known as stereotactic body radiotherapy (SBRT), has been shown to provide excellent local control with a favorable safety profile. Here, we reviewed the retrospective studies and prospective trials that have deployed radiation therapy as LAT in oligometastatic lung cancer, including randomized studies showing benefits for progression-free survival and overall survival with the addition of LAT. We also discuss the impact of targeted therapies and immunotherapy on radiation as LAT.David L. BillingAndreas RimnerMDPI AGarticleoligometastaticnon-small cell lung cancerradiotherapystereotactic body radiotherapylocal ablative therapyNeoplasms. Tumors. Oncology. Including cancer and carcinogensRC254-282ENCancers, Vol 13, Iss 5773, p 5773 (2021)
institution	DOAJ
collection	DOAJ
language	EN
topic	oligometastatic non-small cell lung cancer radiotherapy stereotactic body radiotherapy local ablative therapy Neoplasms. Tumors. Oncology. Including cancer and carcinogens RC254-282
spellingShingle	oligometastatic non-small cell lung cancer radiotherapy stereotactic body radiotherapy local ablative therapy Neoplasms. Tumors. Oncology. Including cancer and carcinogens RC254-282 David L. Billing Andreas Rimner Results of Radiation Therapy as Local Ablative Therapy for Oligometastatic Non-Small Cell Lung Cancer
description	Oligometastatic cancer is characterized by a limited number of metastatic deposits. Compared with lung cancer patients who have more widespread disease, oligometastatic lung cancer patients have more favorable survival outcomes. Therefore, it has been hypothesized that local ablative therapy (LAT) directed at the metastatic deposits in addition to standard-of-care systemic therapy may further improve survival outcomes in oligometastatic lung cancer patients. One LAT modality that has been utilized in oligometastatic lung cancer is radiation therapy. In particular, ultra-hypofractionated radiotherapy, also known as stereotactic body radiotherapy (SBRT), has been shown to provide excellent local control with a favorable safety profile. Here, we reviewed the retrospective studies and prospective trials that have deployed radiation therapy as LAT in oligometastatic lung cancer, including randomized studies showing benefits for progression-free survival and overall survival with the addition of LAT. We also discuss the impact of targeted therapies and immunotherapy on radiation as LAT.
format	article
author	David L. Billing Andreas Rimner
author_facet	David L. Billing Andreas Rimner
author_sort	David L. Billing
title	Results of Radiation Therapy as Local Ablative Therapy for Oligometastatic Non-Small Cell Lung Cancer
title_short	Results of Radiation Therapy as Local Ablative Therapy for Oligometastatic Non-Small Cell Lung Cancer
title_full	Results of Radiation Therapy as Local Ablative Therapy for Oligometastatic Non-Small Cell Lung Cancer
title_fullStr	Results of Radiation Therapy as Local Ablative Therapy for Oligometastatic Non-Small Cell Lung Cancer
title_full_unstemmed	Results of Radiation Therapy as Local Ablative Therapy for Oligometastatic Non-Small Cell Lung Cancer
title_sort	results of radiation therapy as local ablative therapy for oligometastatic non-small cell lung cancer
publisher	MDPI AG
publishDate	2021
url	https://doaj.org/article/117a3ad4f8d24511a647671c915dd762
work_keys_str_mv	AT davidlbilling resultsofradiationtherapyaslocalablativetherapyforoligometastaticnonsmallcelllungcancer AT andreasrimner resultsofradiationtherapyaslocalablativetherapyforoligometastaticnonsmallcelllungcancer
_version_	1718412757919858688

Results of Radiation Therapy as Local Ablative Therapy for Oligometastatic Non-Small Cell Lung Cancer

Ejemplares similares